FSFernanda Cristina dos Santos Simeao

Fernanda Cristina dos Santos Simeao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernanda Cristina dos Santos Simeao has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Off-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in a high-volume reference laboratory

    by Angela Pires Brandao, Fabiane Maria de Almeida Ferreira, Fernanda Cristina dos Santos Simeao, Lucilaine Ferrazoli, Erica Chimara, Rosângela Siqueira de Oliveira, Juliana Maira Watanabe Pinhata

    Drug-resistant tuberculosis (TB) remains a major global health concern. Multidrug-resistant TB is defined by resistance to at least rifampicin (RIF) and isoniazid (INH), the two key drugs used in TB treatment. The BD MAX™ Multi-Drug Resistant Tuberculosis (BD MAX) assay is a fully automated real-time PCR platform, recommended by the World Health Organization for the initial diagnosis of TB and RIF and INH resistance (RIF-R and INH-R) directly from pulmonary clinical samples. This study aimed to assess the off-label performance of BD MAX in clinical M. tuberculosis complex (MTBC) isolates under routine laboratory conditions. The assay was first validated using non-tuberculous mycobacteria (NTM) and MTBC isolates with known mutations. For real-world validation, it was compared to the GenoType MTBDR plus by testing 1,440 clinical isolates prospectively. The BD MAX assay correctly excluded MTBC from all NTM cultures. Among MTBC isolates with known mutations, it identified 19 of 20 RIF-R isolates and 14 of 15 INH-R isolates. In prospective testing, BD MAX achieved 99.8% sensitivity (1,406/1,409), 100% specificity (31/31), and 99.8% (1,437/1,440) overall accuracy for MTBC detection. For drug resistance detection, it showed 95.2% (40/42) concordance for RIF, 96.8% (30/31) for INH and 81.3% (13/16) for MDR when compared to MTBDR plus . Discrepancies between MTBDR plus and BD MAX included heteroresistant cases and unreportable resistance results by BD MAX due to infrequent mutations or low bacterial load. Overall, this study confirms BD MAX as an accurate and reliable tool for MTBC detection and drug resistance profiling in clinical isolates in high-volume TB laboratories. Importance: This study highlights the importance of the BD MAX™ Multi-Drug Resistant Tuberculosis assay (BD MAX) applied in clinical isolates for the detection of multidrug-resistant tuberculosis (MDR-TB), i.e., Mycobacterium tuberculosis resistance to rifampicin and isoniazid. TB is a global health issue, and drug-resistant TB makes treatment more difficult, favoring transmission and disease amplification. The BD MAX platform offers a faster and more automated way to detect TB and drug resistance. The study showed that BD MAX applied off-label in clinical isolates accurately identified TB and resistance to rifampicin and isoniazid, with results comparable to the widely used line probe assay. This is significant in a high-volume laboratory because it is simpler and more rapid than the line probe assay. BD MAX showed some limitations, especially in detecting rare mutations and in cases of low bacteria levels. Overall, this tool could improve TB care, especially in high-volume laboratories.

  • Open Access

    Drug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024

    by Carolina Salgado Pedace, Robert D. Arbeit, Fernanda Cristina dos Santos Simeão, Juliana Failde Gallo, Andréia Rodrigues de Souza, Erica Chimara

    Introduction. Infections caused by Mycobacterium abscessus, an environmentally prevalent, rapidly growing mycobacteria, are increasingly frequent in developed countries. Objective. To analyse the drug susceptibility profiles of M. abscessus isolated in the state of São Paulo from 2008 to 2024. Methods. Of the 2,402 M. abscessus isolates identified during those 17 years, 558 (23.2%) met the American Thoracic Society’s microbiologic and clinical criteria for drug susceptibility testing (DST), which was performed for five agents – clarithromycin, amikacin, cefoxitin, ciprofloxacin, and doxycycline. Results. Clarithromycin showed a dramatic increase in resistance phenotype from ≤10% in the early period to 73–90% over the last 8 years. Over half those isolates demonstrated inducible resistance. Resistance to amikacin was found in fewer than 5% of isolates from 2016 to 2021. In 2022, that result increased to 13%, but for 2023 and 2024, it had fallen back to 2%. Over the past decade, cefoxitin DST has reported the majority of isolates as intermediate, a problematic result in M. abscessus group (MAG) infections, which typically require long-term treatment for successful outcomes. Since 2018, the annual susceptibility rate has been ≤18%, and in five of the 7 years, ≤7%. Ciprofloxacin was typically assessed as susceptible from 2009 to 2011, then decreased sharply to ≤20% over the next several years, and since 2018, the rate has been less than 5%. Through the entire study, doxycycline resistance has remained consistently high; in the years since 2018, ≤6% of isolates have been susceptible. Conclusion. This study demonstrates wide variation among MAG clinical isolates in the frequency of susceptibility, both across different agents and within individual agents over time. These results emphasize the importance of performing high-quality DST on MAG clinical isolates and suggest the need to consider revising the standard panel of drugs tested.